ArticleInternational journal of clinical oncology2025
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.
Mayu Yunokawa et al.PubMed ↗Publisher ↗
No numbers read from the abstract.